Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Study for Scorpion North Africa Middle East Envenomation With a Immune F(ab')2 (Equine) Antivenom Alacramyn NAMO. A Randomized, Double-Blind, Placebo-controlled, Prospective and Multicenter Study

NCT01336660 is registered in ClinicalTrials.gov with Instituto Bioclon S.A. de C.V. as lead sponsor.

NCT NCT01336660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01336660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Study for Scorpion North Africa Middle East Envenomation With a Immune F(ab')2 (Equine) Antivenom Alacramyn NAMO. A Randomized, Double-Blind, Placebo-controlled, Prospective and Multicenter Study
Lead sponsor
Instituto Bioclon S.A. de C.V.
Phase
Phase 2/3
Overall status
Completed
Start date
July 21, 2018
Completion date
November 15, 2018
Enrollment
56 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

poisoning by scorpion sting